Clinical trial
Phase 3, Multicenter,Parallel,Randomized Dbl-masked,Placebo-controlled Study of the Effects of 32 mg/dy Ruboxistaurin Vision Loss in Patients With Type 1 or Type 2 Diabetes Mellitus and an Early Treatment Diabetic Retinopathy Study Level Between 47A and 53E.
NCT00604383 is registered in ClinicalTrials.gov with Chromaderm, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 3, Multicenter,Parallel,Randomized Dbl-masked,Placebo-controlled Study of the Effects of 32 mg/dy Ruboxistaurin Vision Loss in Patients With Type 1 or Type 2 Diabetes Mellitus and an Early Treatment Diabetic Retinopathy Study Level Between 47A and 53E.
- Lead sponsor
- Chromaderm, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 31, 2001
- Completion date
- June 30, 2005
- Enrollment
- 685 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.